Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin
- Development stage
- Approved
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody (polatuzumab) covalently linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable valine-citrulline linker. CD79b is a surface protein specifically expressed on B-cells and is a component of the B-cell receptor complex, making it an ideal target for B-cell malignancies. Upon binding to CD79b, the ADC is internalized into the lysosomal compartment where the linker is cleaved, releasing MMAE into the cytosol. MMAE then binds to tubulin and inhibits its polymerization, resulting in G2/M phase cell cycle arrest and apoptosis. Developed by Genentech (Roche), it is FDA-approved for use in combination with other therapies for the treatment of diffuse large B-cell lymphoma (DLBCL) and is being investigated for other B-cell non-Hodgkin lymphomas, including mantle cell lymphoma.
- Brand names
- Polivy
- Other names
- polatuzumab vedotin-piiq
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCL-2 (BCL-2 family)B-cell antigen receptor complex-associated protein beta chainCD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin.